Patent +1 | CongenPharma's NEW EMPHASES Liquid-Phase Peptide Synthesis Platform Has Already Secured 8 Invention Patents in China, the U.S., and Japan
Publish Time:
2025-11-18
Recently, our company's EMPHASES® new liquid-phase peptide synthesis platform has been granted another Chinese invention patent. To date, the platform has secured a total of 6 Chinese invention patents, 1 U.S. invention patent, and 1 Japanese invention patent, solidifying its position as an industry leader backed by robust technological expertise.
Invention Title: Vitamin E Derivatives, Their Carrier Compounds, and Applications
Patent No.: ZL202411673874.3
The EMPHASES® platform replaces traditional solid-phase resins with a liquid-phase carrier, enabling liquid-liquid reactions and fundamentally addressing industry challenges such as low efficiency, high pollution levels, and elevated costs associated with conventional solid-phase synthesis.
This newly licensed second-generation vector patent not only features shorter synthesis steps and lower costs but also represents a further upgrade of the platform: It optimizes vector solubility to enhance reaction efficiency, maintains high stability during critical stages such as deprotection and condensation—preventing peptide chain loss—and paves the way for advancing peptide synthesis toward greener, more efficient processes with higher yields.
Whether it's drug peptide synthesis in the pharmaceutical field or innovative R&D of cosmetic beauty peptides, the EMPHASES® platform provides core support, delivering more competitive solutions to our customers. Moving forward, Tongjun Pharmaceutical will continue to deepen its commitment to technological innovation, ensuring that sustainable and affordable peptides benefit humanity by enhancing both beauty and health.
